

"the Epstein-Barr virus," as currently recited. In addition, claim 2 was amended to recite "[a]n adenovirus according to claim 1, wherein the Epstein-Barr virus antigen is EBNA1."


CONCLUSION

In view of the foregoing amendments and remarks, the patent owner respectfully requests reconsideration and reexamination of this application and timely allowance of the pending claims.

If there are any fees due in connection with the filing of this Preliminary Amendment not already accounted for, please charge the fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Timothy B. Donaldson
Reg. No. 43,592

Dated: August 31, 2000